Wijk van, J. P. and Hoepelman, A. I. and Koning de, E. and Dallinga-Thie, G. and Rabelink, T. J. and Cabezas, M. C. (2010) Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arteriosclerosis, Thrombosis and Vascular Biology, 31, 228-33. ISSN 1079-5642.
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1161/ATVBAHA.110.216192
OBJECTIVE: To compare the effects of rosiglitazone (8 mg/d, n=19) and metformin (2 g/d, n=18) on postprandial lipemia in patients with HIV-lipodystrophy. METHODS AND RESULTS: Lipodystrophy in HIV is associated with insulin resistance and disturbed postprandial triglyceride and free fatty acid (FFA) metabolism. We conducted an open randomized 6-month study with standardized 10-h oral fat-loading tests at baseline and after treatment. Rosiglitazone (-34%) and metformin (-37%) reduced homeostasis model assessment similarly (P<0.05). Rosiglitazone did not change the area under the curve for FFA and triglyceride; however, it did reduce the area under the curve for hydroxybutyric acid (a marker of hepatic FFA oxidation) by 25% (P<0.05). Rosiglitazone increased the area under the curve for remnantlike particle cholesterol by 40% (P<0.01) compared with baseline. Metformin did not change any of the postprandial measurements. CONCLUSIONS: Rosiglitazone improved insulin sensitivity and decreased postprandial hydroxybutyric acid levels in patients with HIV-lipodystrophy, suggesting improved FFA handling. Despite metabolic improvements, rosiglitazone caused a marked increase in postprandial remnantlike particle cholesterol, which may adversely affect cardiovascular risk. Metformin did not affect postprandial lipemia and could be used to treat insulin resistance in this population.
|Deposited On:||04 Jan 2011 01:00|
|Last Modified:||07 Sep 2011 17:01|
Repository Staff Only: item control page